| Revision as of 12:36, 24 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 447616004 of page Miglitol for the Chem/Drugbox validation project (updated: 'DrugBank'). |
Latest revision as of 21:55, 9 December 2024 edit Citation bot (talk | contribs)Bots5,433,826 edits Added bibcode. | Use this bot. Report bugs. | Suggested by Dominic3203 | Linked from User:Marbletan/sandbox | #UCB_webform_linked 605/2664 |
| Line 1: |
Line 1: |
|
|
{{short description|Chemical compound}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
|
{{cs1 config|name-list-style=vanc|display-authors=6}} |
|
|
{{distinguish|Meglutol}} |
|
|
|
|
{{Drugbox |
|
{{Drugbox |
|
| verifiedrevid = 411550118 |
|
| verifiedrevid = 462252373 |
|
| IUPAC_name = (2''R'',3''R'',4''R'',5''S'')-1-(2-hydroxyethyl)-2-(hydroxymethyl)<br>piperidine-3,4,5-triol |
|
| IUPAC_name = (2''R'',3''R'',4''R'',5''S'')-1-(2-Hydroxyethyl)-2-(hydroxymethyl)<br>piperidine-3,4,5-triol |
|
| image = Miglitol structure.svg |
|
| image = Miglitol2.svg |
|
| width = 200 |
|
| width = 200 |
|
|
| alt = Structural diagram of miglitol |
|
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data--> |
| Line 18: |
Line 22: |
|
| legal_US = Rx-only |
|
| legal_US = Rx-only |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = Oral |
|
| routes_of_administration = ] (]) |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
<!--Pharmacokinetic data--> |
| Line 28: |
Line 32: |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
|
| IUPHAR_ligand = 4842 |
|
| CASNo_Ref = {{cascite|correct|CAS}} |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = 72432-03-2 |
|
| CAS_number = 72432-03-2 |
|
| ATC_prefix = A10 |
|
| ATC_prefix = A10 |
| Line 46: |
Line 51: |
|
|
|
|
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
| C=8 | H=17 | N=1 | O=5 |
|
| C=8 | H=17 | N=1 | O=5 |
|
| molecular_weight = 207.224 g/mol |
|
|
| smiles = OCCN1((O)(O)(O)C1)CO |
|
| smiles = OCCN1((O)(O)(O)C1)CO |
|
| InChI = 1/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1 |
|
|
| InChIKey = IBAQFPQHRJAVAV-ULAWRXDQBK |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1 |
|
| StdInChI = 1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1 |
| Line 58: |
Line 60: |
|
| melting_point = 114 |
|
| melting_point = 114 |
|
}} |
|
}} |
|
|
|
|
|
'''Miglitol''' is an oral ] used in the treatment of ]. It works by reversibly inhibiting ] enzymes in the small intestine, which delays the digestion of complex carbohydrates and subsequently reduces ] glucose levels.<ref name="Scott_2000" /> Approved for clinical use since 1998, miglitol has demonstrated efficacy in improving glycemic control, reducing HbA1c levels, and decreasing both fasting and postprandial plasma glucose concentrations in long-term clinical trials.<ref name="Scott_2000">{{cite journal | vauthors = Scott LJ, Spencer CM | title = Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus | journal = Drugs | volume = 59 | issue = 3 | pages = 521–49 | date = March 2000 | pmid = 10776834 | doi = 10.2165/00003495-200059030-00012 }}</ref><ref name="medline">{{cite web |url=https://www.nlm.nih.gov/medlineplus/druginfo/meds/a601079.html |title=Migliotl: MedlinePlus Drug Information |author=<!--Staff writer(s); no by-line.--> |date=1 September 2010 |work=MedlinePlus |publisher=National Institutes of Health |access-date=13 April 2013}}</ref> Additionally, recent studies have suggested that miglitol may have potential as an anti-obesity agent, showing promise in reducing body weight and body mass index in obese or diabetic patients.<ref name="Sugimoto_2015">{{cite journal | vauthors = Sugimoto S, Nakajima H, Kosaka K, Hosoi H | title = Review: Miglitol has potential as a therapeutic drug against obesity | journal = Nutrition & Metabolism | volume = 12 | issue = | pages = 51 | date = 2015 | pmid = 26628904 | pmc = 4666030 | doi = 10.1186/s12986-015-0048-8 | doi-access = free }}</ref> While generally well-tolerated, the most common side effects associated with miglitol are gastrointestinal disturbances, which are typically mild to moderate and tend to decrease over time.<ref name="Scott_2000" /> |
|
|
|
|
|
It must be taken at the start of main meals to have maximal effect<ref name="FDA">{{cite web |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf|title=Glyset (miglitol) tablets label - Accessdata FDA|author=<!--Staff writer(s); no by-line.--> |date=August 2012 |work=Drugs@FDA|publisher=U.S. Food and Drug Administration |access-date=13 April 2013}}</ref> |
|
|
|
|
|
In contrast to ] (another ] inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys. |
|
|
|
|
|
== Formulation == |
|
|
The benefits of alpha-glucosidase inhibitors on health were shown to be stronger when the powder is consumed orally dissolved in water as a beverage in comparison to its intake as ordinary hard gelatin capsules.<ref name=":0">{{cite journal | vauthors = Moreira FD, Reis CE, Gallassi AD, Moreira DC, Welker AF | title = Suppression of the postprandial hyperglycemia in patients with type 2 diabetes by a raw medicinal herb powder is weakened when consumed in ordinary hard gelatin capsules: A randomized crossover clinical trial | journal = PLOS ONE | volume = 19 | issue = 10 | pages = e0311501 | date = 2024-10-09 | pmid = 39383145 | pmc = 11463819 | doi = 10.1371/journal.pone.0311501 | veditors = Dardari D | doi-access = free | bibcode = 2024PLoSO..1911501M }}{{Creative Commons text attribution notice|cc=by4|from this source=yes}}</ref> |
|
|
|
|
|
==See also== |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
|
|
|
==References== |
|
|
{{reflist}} |
|
|
|
|
|
{{Oral hypoglycemics}} |
|
|
|
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
|
|
|
|
|
|
{{gastrointestinal-drug-stub}} |